Avail is conducting a 12-week, Phase 2, Randomized
Study to Evaluate the Safety and Efficacy of a new drug in Subjects with
Chronic Hepatitis C Infection.
*To see if you qualify for this Hepatitis C Clinical Trial, visit Avail Clinical Research on the web or contact us directly at (386) 785-2404.
The primary objectives of this Hep C Clinical Study are to evaluate the:
Safety and tolerability of a new Hep C drug and simeprevir when given in combination with RBV for up to 12 weeks.